FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Richard Simon

Research Profile

Procedures

Devices

Oligonucleotide Array Sequence Analysis

Concepts & Ideas

Disorders

Activities & Behaviors

Occupations

Computational Biology

Chemicals & Drugs

Physiology

Gene Expression Regulation, Neoplastic

Co-author Network

Publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Richard Simon (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Richard Simon; Sameek Roychowdhury
Implementing personalized cancer genomics in clinical trials.
Nature reviews. Drug discovery 2013;12(5):358-69.
2012: Richard Simon
Clinical trials for predictive medicine.
Statistics in medicine 2012;31(25):3031-40.
2012: Ahrim Youn; Richard Simon
Estimating the order of mutations during tumorigenesis from tumor genome sequencing data.
Bioinformatics (Oxford, England) 2012;28(12):1555-61.
2012: Stella Wanjugu Karuri; Richard Simon
A two-stage Bayesian design for co-development of new drugs and companion diagnostics.
Statistics in medicine 2012;31(10):901-14.
2011: Kyung In Kim; Richard Simon
Probabilistic classifiers with high-dimensional data.
Biostatistics (Oxford, England) 2011;12(3):399-412.
2011: Jyothi Subramanian; Richard Simon
An evaluation of resampling methods for assessment of survival risk prediction in high-dimensional settings.
Statistics in medicine 2011;30(6):642-53.
2011: Ahrim Youn; Richard Simon
Identifying cancer driver genes in tumor genome sequencing studies.
Bioinformatics (Oxford, England) 2011;27(2):175-81.
2011: Xiaosheng Wang; Richard Simon
Microarray-based cancer prediction using single genes.
BMC bioinformatics 2011;12():391.
2010: Richard Simon
Clinical trials for predictive medicine: new challenges and paradigms.
Clinical trials (London, England) 2010;7(5):516-24.
2010: Richard Simon
Moving from correlative science to predictive oncology.
The EPMA journal 2010;1(3):377-87.
2010: Jyothi Subramanian; Richard Simon
What should physicians look for in evaluating prognostic gene-expression signatures?
Nature reviews. Clinical oncology 2010;7(6):327-34.
2010: Jyothi Subramanian; Richard Simon
Gene expression-based prognostic signatures in lung cancer: ready for clinical use?
Journal of the National Cancer Institute 2010;102(7):464-74.
2010: Mireia Sospedra; Yingdong Zhao; Marc Giulianotti; Richard Simon; Clemencia Pinilla; Roland Martin
Combining positional scanning peptide libraries, HLA-DR transfectants and bioinformatics to dissect the epitope spectrum of HLA class II cross-restricted CD4+ T cell clones.
Journal of immunological methods 2010;353(1-2):93-101.
2010: Boris Freidlin; Wenyu Jiang; Richard Simon
The cross-validated adaptive signature design.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(2):691-8.
2010: Yingdong Zhao; Richard Simon
Gene expression deconvolution in clinical samples.
Genome medicine 2010;2(12):93.
2010: Richard Simon
Translational research in oncology: key bottlenecks and new paradigms.
Expert reviews in molecular medicine 2010;12():e32.
2010: Yingdong Zhao; Richard Simon
Development and validation of predictive indices for a continuous outcome using gene expression profiles.
Cancer informatics 2010;9():105-14.
2009: Sally Hunsberger; Yingdong Zhao; Richard Simon
A comparison of phase II study strategies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):5950-5.
2009: Tatiana Vidaurre; Julia Wilkerson; Richard Simon; Susan E Bates; Tito Fojo
Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development.
Cancer journal (Sudbury, Mass.) 2009;15(5):366-73.
2009: Richard Simon
Analysis of DNA microarray expression data.
Best practice & research. Clinical haematology 2009;22(2):271-82.
2008: Richard Simon
Lost in translation: problems and pitfalls in translating laboratory observations to clinical utility.
European journal of cancer (Oxford, England : 1990) 2008;44(18):2707-13.
2008: Richard Simon
The use of genomics in clinical trial design.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(19):5984-93.
2008: Richard Simon
Interpretation of genomic data: questions and answers.
Seminars in hematology 2008;45(3):196-204.
2008: Richard Simon
Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics.
Expert opinion on medical diagnostics 2008;2(6):721-9.
2008: Richard Simon
Challenges of microarray data and the evaluation of gene expression profile signatures.
Cancer investigation 2008;26(4):327-32.
2008: Richard Simon; Xinan Zhang
On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations.
International journal of cancer. Journal international du cancer 2008;122(8):1916-7.
2008: Richard Simon
Microarray-based expression profiling and informatics.
Current opinion in biotechnology 2008;19(1):26-9.
2008: Yingdong Zhao; Richard Simon
BRB-ArrayTools Data Archive for human cancer gene expression: a unique and efficient data sharing resource.
Cancer informatics 2008;6():9-15.
2008: Xiaojiang Xu; Yingdong Zhao; Richard Simon
Gene Set Expression Comparison kit for BRB-ArrayTools.
Bioinformatics (Oxford, England) 2008;24(1):137-9.
2007: Wenyu Jiang; Richard Simon
A comparison of bootstrap methods and an adjusted bootstrap approach for estimating the prediction error in microarray classification.
Statistics in medicine 2007;26(29):5320-34.
2007: Edward L Korn; Ming-Chung Li; Lisa M McShane; Richard Simon
An investigation of two multivariate permutation methods for controlling the false discovery proportion.
Statistics in medicine 2007;26(24):4428-40.
2007: Wenyu Jiang; Boris Freidlin; Richard Simon
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Journal of the National Cancer Institute 2007;99(13):1036-43.
2007: Richard Simon; Amy Lam; Ming-Chung Li; Michael Ngan; Supriya Menenzes; Yingdong Zhao
Analysis of gene expression data using BRB-ArrayTools.
Cancer informatics 2007;3():11-7.
2007: Yingdong Zhao; Myong-Hee Sung; Richard Simon
Artificial intelligence methods for predicting T-cell epitopes.
Methods in molecular biology (Clifton, N.J.) 2007;409():217-25.
2007: Richard Simon
New challenges for 21st century clinical trials.
Clinical trials (London, England) 2007;4(2):167-9; discussion 173-7.
2007: Marian Grade; Patrick Hörmann; Sandra Becker; Amanda B Hummon; Danny Wangsa; Sudhir Varma; Richard Simon; Torsten Liersch; Heinz Becker; Michael J Difilippantonio; B Michael Ghadimi; Thomas Ried
Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas.
Cancer research 2007;67(1):41-56.
2006: David N Danforth; Andrea Abati; Armando C Filie; Sheila A Prindiville; Diane Palmieri; Richard Simon; Thomas Ried; Patricia S Steeg
Combined breast ductal lavage and ductal endoscopy for the evaluation of the high-risk breast: a feasibility study.
Journal of surgical oncology 2006;94(7):555-64.
2006: Richard Simon; Larry Norton
The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens.
Nature clinical practice. Oncology 2006;3(8):406-7.
2006: Richard Simon
A checklist for evaluating reports of expression profiling for treatment selection.
Clinical advances in hematology & oncology : H&O 2006;4(3):219-24.
2006: Richard Simon
Validation of pharmacogenomic biomarker classifiers for treatment selection.
Cancer biomarkers : section A of Disease markers 2006;2(3-4):89-96.
2006: Sudhir Varma; Richard Simon
Bias in error estimation when using cross-validation for model selection.
BMC bioinformatics 2006;7():91.
2006: Marian Grade; B Michael Ghadimi; Sudhir Varma; Richard Simon; Danny Wangsa; Linda Barenboim-Stapleton; Torsten Liersch; Heinz Becker; Thomas Ried; Michael J Difilippantonio
Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas.
Cancer research 2006;66(1):267-82.
2005: Silva Markovic-Plese; Bernhard Hemmer; Yingdong Zhao; Richard Simon; Clemencia Pinilla; Roland Martin
High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T-cell response: implications for the initiation of autoimmune response in multiple sclerosis.
Journal of neuroimmunology 2005;169(1-2):31-8.
2005: Boris Freidlin; Richard Simon
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7872-8.
2005: Richard Simon
Roadmap for developing and validating therapeutically relevant genomic classifiers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(29):7332-41.
2005: Boris Freidlin; Richard Simon
Evaluation of randomized discontinuation design.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(22):5094-8.
2005: Xinan Zhang; Richard Simon
Estimating the number of rate limiting genomic changes for human breast cancer.
Breast cancer research and treatment 2005;91(2):121-4.
2005: B Michael Ghadimi; Marian Grade; Michael J Difilippantonio; Sudhir Varma; Richard Simon; Cristina Montagna; László Füzesi; Claus Langer; Heinz Becker; Torsten Liersch; Thomas Ried
Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(9):1826-38.
2005: Aboubakar Maitournam; Richard Simon
On the efficiency of targeted clinical trials.
Statistics in medicine 2005;24(3):329-39.
2005: Richard Simon
Clinical trial designs for therapeutic cancer vaccines.
Cancer treatment and research 2005;123():339-50.
2005: Yingdong Zhao; Ming-Chung Li; Richard Simon
An adaptive method for cDNA microarray normalization.
BMC bioinformatics 2005;6():28.
2005: Kevin Dobbin; Richard Simon
Sample size determination in microarray experiments for class comparison and prognostic classification.
Biostatistics (Oxford, England) 2005;6(1):27-38.
2004: Myong-Hee Sung; Richard Simon
Candidate epitope identification using peptide property models: application to cancer immunotherapy.
Methods (San Diego, Calif.) 2004;34(4):460-7.
2004: Richard Simon
When is a genomic classifier ready for prime time?
Nature clinical practice. Oncology 2004;1(1):4-5.
2004: Richard Simon; Aboubakar Maitournam
Evaluating the efficiency of targeted designs for randomized clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(20):6759-63.
2004: Sudhir Varma; Richard Simon
Iterative class discovery and feature selection using Minimal Spanning Trees.
BMC bioinformatics 2004;5():126.
2004: Myong-Hee Sung; Richard Simon
In silico simulation of inhibitor drug effects on nuclear factor-kappaB pathway dynamics.
Molecular pharmacology 2004;66(1):70-5.
2004: Bibiana Bielekova; Myong-Hee Sung; Nadja Kadom; Richard Simon; Henry McFarland; Roland Martin
Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis.
Journal of immunology (Baltimore, Md. : 1950) 2004;172(6):3893-904.
2004: Myong-Hee Sung; Richard Simon
Genomewide conserved epitope profiles of HIV-1 predicted by biophysical properties of MHC binding peptides.
Journal of computational biology : a journal of computational molecular cell biology 2004;11(1):125-45.
2003: Yingdong Zhao; Clemencia Pinilla; Danila Valmori; Roland Martin; Richard Simon
Application of support vector machines for T-cell epitopes prediction.
Bioinformatics (Oxford, England) 2003;19(15):1978-84.
2003: Kevin Dobbin; Joanna H Shih; Richard Simon
Questions and answers on design of dual-label microarrays for identifying differentially expressed genes.
Journal of the National Cancer Institute 2003;95(18):1362-9.
2003: Richard Simon
Using DNA microarrays for diagnostic and prognostic prediction.
Expert review of molecular diagnostics 2003;3(5):587-95.
2003: Oleg K Glebov; Luz M Rodriguez; Kenneth Nakahara; Jean Jenkins; Janet Cliatt; Casey Humbyrd; John DeNobile; Peter Soballe; Richard Simon; George Wright; Patrick Lynch; Sherri Patterson; Henry T Lynch; Steven Gallinger; Aby Buchbinder; Gary Gordon; Ernest T Hawk; Ilan R Kirsch
Distinguishing right from left colon by the pattern of gene expression.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(8):755-62.
2003: James R Vasselli; Joanna H Shih; Shuba R Iyengar; Jodi K Maranchie; Joseph Riss; Robert Worrell; Carlos Torres-Cabala; Ray Tabios; Andra Mariotti; Robert Stearman; Maria Merino; McClellan Walther; Richard Simon; Richard D Klausner; W Marston Linehan
Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(12):6958-63.
2003: Carolyn J M Best; Isabel M Leiva; Rodrigo F Chuaqui; John W Gillespie; Paul H Duray; Meera Murgai; Yingdong Zhao; Richard Simon; Jason J Kang; Jeffrey E Green; David G Bostwick; W Marston Linehan; Michael R Emmert-Buck
Molecular differentiation of high- and moderate-grade human prostate cancer by cDNA microarray analysis.
Diagnostic molecular pathology : the American journal of surgical pathology, part B 2003;12(2):63-70.
2003: Kevin Dobbin; Joanna H Shih; Richard Simon
Statistical design of reverse dye microarrays.
Bioinformatics (Oxford, England) 2003;19(7):803-10.
2003: Richard Simon; Michael D Radmacher; Kevin Dobbin; Lisa M McShane
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.
Journal of the National Cancer Institute 2003;95(1):14-8.
2002: Lisa M McShane; Michael D Radmacher; Boris Freidlin; Ren Yu; Ming-Chung Li; Richard Simon
Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data.
Bioinformatics (Oxford, England) 2002;18(11):1462-9.
2002: Kevin Dobbin; Richard Simon
Comparison of microarray designs for class comparison and class discovery.
Bioinformatics (Oxford, England) 2002;18(11):1438-45.
2002: Richard Simon
Bayesian subset analysis: application to studying treatment-by-gender interactions.
Statistics in medicine 2002;21(19):2909-16.
2002: Richard Simon; Michael D Radmacher; Kevin Dobbin
Design of studies using DNA microarrays.
Genetic epidemiology 2002;23(1):21-36.
2002: Koh Miura; Elise D Bowman; Richard Simon; Amy C Peng; Ana I Robles; Raymond T Jones; Toyomasa Katagiri; Ping He; Hiroki Mizukami; Lu Charboneau; Takefumi Kikuchi; Lance A Liotta; Yusuke Nakamura; Curtis C Harris
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles.
Cancer research 2002;62(11):3244-50.
2002: Kartiki V Desai; Nianqing Xiao; Weili Wang; Lisa Gangi; John Greene; John I Powell; Robert Dickson; Priscilla A Furth; Kent Hunter; Raju Kucherlapati; Richard Simon; Edison Liu; Jeffrey E Green
Initiating oncogenic event determines gene-expression patterns of human breast cancer models.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(10):6967-72.
2002: Myong-Hee Sung; Yingdong Zhao; Roland Martin; Richard Simon
T-cell epitope prediction with combinatorial peptide libraries.
Journal of computational biology : a journal of computational molecular cell biology 2002;9(3):527-39.
2002: Michael D Radmacher; Lisa M McShane; Richard Simon
A paradigm for class prediction using gene expression profiles.
Journal of computational biology : a journal of computational molecular cell biology 2002;9(3):505-11.
2001: Yingdong Zhao; Bruno Gran; Clemencia Pinilla; Silva Markovic-Plese; Bernhard Hemmer; A Tzou; LW Whitney; William E Biddison; Roland Martin; Richard Simon
Combinatorial peptide libraries and biometric score matrices permit the quantitative analysis of specific and degenerate interactions between clonotypic TCR and MHC peptide ligands.
Journal of immunology (Baltimore, Md. : 1950) 2001;167(4):2130-41.
2001: Roland Martin; Bruno Gran; Yingdong Zhao; Silva Markovic-Plese; Bibiana Bielekova; Adriana Marques; Myong-Hee Sung; Bernhard Hemmer; Richard Simon; Henry McFarland; Clemencia Pinilla
Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease.
Journal of autoimmunity 2001;16(3):187-92.
2001: Edward L Korn; Arbuck Susan; James M Pluda; Richard Simon; Richard S. Kaplan; Michaele C Christian
Clinical trial designs for cytostatic agents: are new approaches needed?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(1):265-72.
2000: TT Chen; John P Chute; Ellen G Feigal; Bruce E Johnson; Richard Simon
A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer.
Journal of the National Cancer Institute 2000;92(19):1601-7.
2000: Michael D Radmacher; Richard Simon
Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors.
Journal of the National Cancer Institute 2000;92(1):48-53.
1999: Bernhard Hemmer; Bruno Gran; Yingdong Zhao; Adriana Marques; J Pascal; A Tzou; T Kondo; I Cortese; Bibiana Bielekova; S E Straus; Henry McFarland; Richard A Houghten; Richard Simon; Clemencia Pinilla; Roland Martin
Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease.
Nature medicine 1999;5(12):1375-82.
1999: Richard Simon
Bayesian design and analysis of active control clinical trials.
Biometrics 1999;55(2):484-7.
1999: John P Chute; T Chen; Ellen G Feigal; Richard Simon; Bruce E Johnson
Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1794-801.
1998: Malcolm A Smith; Boris Freidlin; Lynn A G Ries; Richard Simon
Trends in reported incidence of primary malignant brain tumors in children in the United States.
Journal of the National Cancer Institute 1998;90(17):1269-77.
1998: Victor A Sandor; V Stark-Vancs; Deborah Pearson; R Nussenblat; Scott M Whitcup; Pim Brouwers; N Patronas; John D Heiss; Elaine S Jaffe; M deSmet; David R Kohler; Richard Simon; Robert Wittes
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3000-6.
1997: Malcolm A Smith; T Chen; Richard Simon
Age-specific incidence of acute lymphoblastic leukemia in U.S. children: in utero initiation model.
Journal of the National Cancer Institute 1997;89(20):1542-4.
1997: Richard Simon; Boris Freidlin; Lawrence V Rubinstein; Arbuck Susan; J Collins; Michaele C Christian
Accelerated titration designs for phase I clinical trials in oncology.
Journal of the National Cancer Institute 1997;89(15):1138-47.
1997: Malcolm A Smith; R S Ungerleider; Edward L Korn; Lawrence V Rubinstein; Richard Simon
Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2736-43.
1996: Edward L Korn; Richard Simon
Data monitoring committees and problems of lower-than-expected accrual or events rates.
Controlled clinical trials 1996;17(6):526-35.
1996: D Faraggi; Richard Simon
A simulation study of cross-validation for selecting an optimal cutpoint in univariate survival analysis.
Statistics in medicine 1996;15(20):2203-13.
1996: M Smith; D Arthur; Bruce M Camitta; Andrew J Carroll; William M Crist; Paul S Gaynon; R Gelber; N Heerema; Edward L Korn; Michael Link; S Murphy; Ching-Hon Pui; Jeanette Pullen; G Reamon; Stephen E Sallan; Harland Sather; J Shuster; Richard Simon; Michael E Trigg; DG Tubergen; fatih uckun; R Ungerleider
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):18-24.
1995: Laurence S Freedman; Richard Simon; M A Foulkes; L Friedman; N L Geller; D J Gordon; R Mowery
Inclusion of women and minorities in clinical trials and the NIH Revitalization Act of 1993--the perspective of NIH clinical trialists.
Controlled clinical trials 1995;16(5):277-85; discussion 286-9, 293-309.
1995: N Strauss; Richard Simon
Investigating a sequence of randomized phase II trials to discover promising treatments.
Statistics in medicine 1995;14(13):1479-89.
1995: D Faraggi; Richard Simon
A neural network model for survival data.
Statistics in medicine 1995;14(1):73-82.
1994: Richard Simon
Randomized clinical trials in oncology. Principles and obstacles.
Cancer 1994;74(9 Suppl):2614-9.
1994: T T Chen; Richard Simon
A multiple decision procedure in clinical trials.
Statistics in medicine 1994;13(5-7):431-46.
1994: Richard Simon; P F Thall; S S Ellenberg
New designs for the selection of treatments to be tested in randomized clinical trials.
Statistics in medicine 1994;13(5-7):417-29.
1993: T T Chen; Richard Simon
A multiple-step selection procedure with sequential protection of preferred treatments.
Biometrics 1993;49(3):753-61.
1993: M Smith; Richard Simon; D Cain; R S Ungerleider
Children and cancer. A perspective from the Cancer Therapy Evaluation Program, National Cancer Institute.
Cancer 1993;71(10 Suppl):3422-8.
1993: Edward L Korn; Richard Simon
Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(4):794-801.
1992: V Torri; Richard Simon; E Russek-Cohen; Douglas Midthune; M Friedman
Relationship between response and survival in patients with advanced ovarian cancer.
Journal of the National Cancer Institute 1992;84(11):899-900.
1992: V Torri; Richard Simon; E Russek-Cohen; Douglas Midthune; M Friedman
Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy.
Journal of the National Cancer Institute 1992;84(6):407-14.
1991: Richard Simon
A decade of progress in statistical methodology for clinical trials.
Statistics in medicine 1991;10(12):1789-817.
1991: Malcolm A Smith; R S Ungerleider; M E Horowitz; Richard Simon
Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma.
Journal of the National Cancer Institute 1991;83(20):1460-70.
1991: S Durrleman; Richard Simon
When to randomize?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(1):116-22.
1990: Richard Simon; Edward L Korn
Selecting drug combinations based on total equivalent dose (dose intensity)
Journal of the National Cancer Institute 1990;82(18):1469-76.
1990: S Durrleman; Richard Simon
Planning and monitoring of equivalence studies.
Biometrics 1990;46(2):329-36.
1990: P F Thall; Richard Simon
Incorporating historical control data in planning phase II clinical trials.
Statistics in medicine 1990;9(3):215-28.
1990: Richard Simon; S Durrleman; R T Hoppe; G Bonadonna; C D Bloomfield; R A Rudders; Bruce D Cheson; C W Berard
Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.
Medical and pediatric oncology 1990;18(2):89-96.
1989: P F Thall; Richard Simon; S S Ellenberg
A two-stage design for choosing among several experimental treatments and a control in clinical trials.
Biometrics 1989;45(2):537-47.
1989: Richard Simon
Optimal two-stage designs for phase II clinical trials.
Controlled clinical trials 1989;10(1):1-10.
1988: P F Thall; Richard Simon; S S Ellenberg; R Shrager
Optimal two-stage designs for clinical trials with binary response.
Statistics in medicine 1988;7(5):571-9.